In the burgeoning RNAi sector, a handful of companies are working to develop the technology into a source of human therapeutics. Only one — Sirna Therapeutics — has said that it expects to have an RNAi drug ready for clinical trials next year.
But now, a Philadelphia-based start-up is pushing into the foreground with a seasoned biotech player in front and a even more ambitious timeline than its bigger rival.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.